Prelude Therapeutics Inc. Annual Report - A Deep Dive for Investors

This summary provides a clear, jargon-free analysis of Prelude Therapeutics' performance and strategic direction for the fiscal year ended December 31, 2025. Based on their latest 10-K filing, we aim to offer retail investors a comprehensive understanding of this clinical-stage biotech company, highlighting its potential and the challenges it faces.

Business Overview: Pioneering Precision Oncology

Prelude Therapeutics is a biopharmaceutical company focused on discovering and developing new small molecule therapies for cancer. The company's mission is to address significant unmet medical needs by targeting specific biological pathways that drive cancer growth. Prelude achieves this through an internal process that combines deep cancer biology insights with advanced medicinal chemistry and structural analysis. This approach allows them to design highly selective and potent drug candidates, including kinase inhibitors, targeted protein degraders, and precision antibody-drug conjugates (ADCs). Prelude develops all these candidates in-house, maintaining intellectual property and control.

Pipeline Progress: Advancing Key Programs

Prelude's pipeline includes several promising drug candidates, with a strong focus on moving them through clinical development. Here is an update on their key programs as of December 31, 2025:

• PRT811 (Kinase Inhibitor): This is Prelude's most advanced program. It is currently in Phase 2 clinical trials for patients with certain brain and spinal cord cancers (CNS tumors) and other solid tumors. The company also evaluates PRT811 in Phase 1 trials for various blood cancers (hematologic malignancies). Prelude anticipates providing further clinical updates and potential expansion cohorts for PRT811 in 2026.
• PRT1419 (Targeted Protein Degrader): This novel degrader is in Phase 1 clinical trials for solid tumors and blood cancers. The company expects initial data from this trial in late 2026 or early 2027, focusing on safety, tolerability, and preliminary signs of efficacy.
• PRT2527 (Kinase Inhibitor): Also in Phase 1 clinical trials for solid tumors and blood cancers, with similar data expectations to PRT1419.
• PRT3789 (Targeted Protein Degrader): This program is in the IND-enabling stage, meaning Prelude is preparing it for submission to regulatory authorities to begin human clinical trials. The company targets submitting an Investigational New Drug (IND) application in mid-2026.
• PRT7732 (Antibody Drug Conjugate): This program remains in the discovery stage, with preclinical studies ongoing to identify a lead candidate.
• Partnered Program with AbCellera Biologics, Inc.: Prelude collaborates with AbCellera to develop a novel ADC. Under this agreement, AbCellera discovers antibodies, while Prelude handles preclinical and clinical development. This partnership includes potential milestone payments and royalties to AbCellera upon successful development and commercialization.

Since its inception in 2016, Prelude has successfully moved multiple programs from discovery into human clinical trials—a significant achievement for an early-stage biotech. However, investors must remember that all clinical programs carry a substantial risk of failure.

Financial Performance: Investing in Innovation

As a clinical-stage biotechnology company, Prelude Therapeutics currently generates no revenue from product sales. Their financial performance for the fiscal year ended December 31, 2025, reflects significant investment in research and development (R&D):

• Revenue: $0 million (typical for a pre-commercial company).
• Net Loss: The company reported a net loss of approximately $125 million for the year. R&D expenses and general administrative costs primarily drove this loss. This represents a slight increase from the previous year, reflecting accelerated clinical trial activities.
• Research & Development (R&D) Expenses: R&D expenses totaled approximately $105 million, accounting for most of their operating costs. This investment supports ongoing clinical trials, preclinical development, and discovery efforts.

Financial Health: Liquidity and Capital Resources

• Cash and Cash Equivalents: As of December 31, 2025, Prelude held approximately $180 million in cash, cash equivalents, and marketable securities.
• Cash Runway: Based on current operating expenses and projected R&D spend, management estimates their existing cash resources will fund operations into late 2027. This estimate does not include potential future capital raises or significant partnership agreements.
• Debt: The company reported no significant long-term debt as of December 31, 2025, primarily relying on equity financing to fund its operations.
• Market Capitalization: As of early March 2026, Prelude Therapeutics had approximately 63 million shares outstanding, with a market capitalization of around $150 million. This valuation reflects its early-stage nature and the inherent risks and potential rewards of its pipeline.

Management's Discussion and Analysis (MD&A) Highlights

Management attributes the increased net loss primarily to the accelerated clinical trial activities for its lead programs, particularly PRT811, and continued investment in preclinical development and discovery efforts. General and administrative expenses also contributed to operating costs, supporting the company's growth and infrastructure.

As a pre-commercial entity, Prelude funds its operations through equity financings and generates no revenue from product sales. The company focuses on prudent capital allocation to extend its cash runway while aggressively pursuing clinical milestones. Prelude's financial condition reflects its stage of development, characterized by significant R&D investment and a reliance on external capital to fund operations.

Key Risks for Investors

Investing in Prelude Therapeutics, like any clinical-stage biotech, involves significant risks:

• Clinical Trial Success: The primary risk is that drug candidates may fail to demonstrate safety or efficacy in clinical trials, or may not receive regulatory approval. Any trial failure could significantly impact the company's value.
• Regulatory Approval: Even with positive clinical data, no guarantee exists that the FDA or other regulatory bodies will approve their drugs for commercialization.
• Funding and Cash Runway: Prelude depends on raising additional capital to fund its operations beyond late 2027. Future financing may not be available on favorable terms, or at all, which could force program delays or abandonment.
• Competition: The oncology market is highly competitive. Even if successful, Prelude's drugs may face intense competition from existing therapies or new treatments developed by larger, more established pharmaceutical companies.
• Intellectual Property: The company's success depends on its ability to obtain and maintain patent protection for its drug candidates. Any challenges to their patents could significantly harm their competitive position.
• Reliance on Key Personnel: Prelude's success highly depends on its ability to attract and retain qualified scientific and management personnel.

Competitive Position

The biopharmaceutical industry, particularly in oncology, is highly competitive and experiences rapid technological change. Prelude Therapeutics competes with numerous pharmaceutical and biotechnology companies, many of which possess significantly greater financial, technical, and human resources.

Prelude's competitive strategy relies on its internal process for identifying novel targets and developing differentiated small molecule therapies with unique mechanisms of action. Its in-house development approach aims to maintain intellectual property control and accelerate program advancement. While the company believes its pipeline candidates, if successful, could address significant unmet medical needs, competition from existing approved therapies, therapies in development by competitors, and new technologies could limit their market potential.

Key competitive factors include:

• Product efficacy
• Safety
• Convenience
• Price
• Market access

Future Outlook and Strategic Focus

Prelude's strategy for the coming year centers on advancing its clinical pipeline, particularly PRT811 through Phase 2, and initiating human trials for PRT3789. They aim to generate meaningful clinical data to validate their internal discovery process and attract potential strategic partners for later-stage development or commercialization. The company will also continue to explore new targets and expand its preclinical pipeline, leveraging its in-house capabilities. Management emphasizes a disciplined approach to capital allocation, focusing resources on programs with the highest probability of success and addressing significant unmet medical needs.

In summary, Prelude Therapeutics is an early-stage biotech company with a focused approach to precision oncology and a pipeline of internally developed assets. While the company has made progress in advancing programs into clinical trials, it faces substantial financial and developmental risks inherent to the industry. Investors should weigh the potential for significant returns against the high probability of clinical and financial setbacks.